MITF and melanoma: The current study provides an example of how a better mechanistic understanding may contribute to this in that it not only uncovers an on-target adverse effect of IDO1 inhibition but also raises the possibility that pharmacologic MITF intervention might be explored to improve immunotherapy outcome of patients with melanoma.